Mark McClellan

That argument was first famously raised by the then U.S. FDA Commissioner Mark McClellan before the First International Colloquium on Generic Medicine in Cancun, Mexico (September 25, 2003). It was raised again by the Republican Policy Committee of the United States Senate (2005). Its policy statement, Pharmaceutical Price Controls Abroad An Unfair Trade Policy, cited the 2002 U.S. Trade Promotion Authority Act, which acknowledged that price controls and reference pricing for pharmaceutical products (to be discussed below) are trade-distorting... 

Cutler, David M., and Mark McClellan. 2001a. Is Technological Change in Medicine Worth It Health Affairs 20(5) 11-29. 

Cutler, David, Mark McClellan, and Joseph Newhouse. 1997. The Costs and Benefits of Intensive Treatment for Cardiovascular Disease. Paper presented at AEl-Brookings Conference on Measuring the Prices of Medical Treatments, December 12. 

Mark McClellan, a physician and economist who led the FDA from 2002 to 2004. As FDA commissioner in the Bush administration, he opposed government regulation of the pharmaceutical industry and criticized European countries for inhibiting drug innovation with price controls. 

Through the activities of the then new—since November 2002—but since departed commissioner of Food and Drugs, Mark B. McClellan, M.D., Ph.D., the FDA had recently launched five major initiatives for Efficient Risk Management, Better Informed Consumers, Patient and Consumer Safety, Counterterrorism, and to build a Strong FDA. ... 

An example of a drug approved under the accelerated approval program of the FDA is Gleevec In May 2001, it was approved for treatment of chronic myeloid leukemia (CML), a life-threatening cancer that affects 40,000 people in the United States. Mark B. McClellan, M.D., Ph.D., at that time Commissioner of the Food and Drug Administration, said, Our... 

President George W. Bush chose Mark McClellan, another overachiever with degrees in medicine and economics, to head FDA. By the time that McClellan took over, the pace of drug approvals was slowing, and the pharmaceuti-... 

---